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Background: Depression is a risk factor for worse outcomes in 
persons living with HIV/AIDS and has a prevalence more than three 
times as high as in the general population. Despite this, there are few 
randomized studies of antidepressants in HIV-infected Africans. 
Methods: We enrolled 460 HIV-infected Africans with cryptococcal 
meningitis into a randomized clinical trial of adjunctive sertraline vs 
placebo (2015-2017). We defined depression using depression using a 
Center for Epidemiologic Studies Depression Scale (CES-D) score of 
>15, and severe depression as >26 at one and three months after 
meningitis diagnosis and initiation of treatment.We evaluated the 
relationship between sertraline and depression, as well as 
associations with persistent depression, at three months. 
Results: At one- and three-months post meningitis diagnosis, 62% 
(108/174) and 44% (74/169) of all subjects had depression (CES>15), 
Open Peer Review




26 Feb 2021 report
Nathan Ford, World Health Organization, 
Geneva, Switzerland
1. 
Any reports and responses or comments on the 
article can be found at the end of the article.
 
Page 1 of 10
Wellcome Open Research 2021, 6:45 Last updated: 19 APR 2021
Corresponding author: Sarah M. Lofgren (lofg0020@umn.edu)
Author roles: Lofgren SM: Conceptualization, Formal Analysis, Funding Acquisition, Investigation, Methodology, Validation, 
Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Velamakanni SS: Formal Analysis, Writing – Original Draft 
Preparation, Writing – Review & Editing; Huppler Hullsiek K: Formal Analysis, Methodology, Project Administration, Writing – Review & 
Editing; Bangdiwala AS: Data Curation, Formal Analysis, Writing – Review & Editing; Namudde A: Investigation, Writing – Review & 
Editing; Musubire AK: Investigation, Writing – Review & Editing; Mpoza E: Investigation, Writing – Review & Editing; Abassi M: 
Investigation, Writing – Review & Editing; Pastick KA: Data Curation, Investigation, Writing – Review & Editing; Nuwagira E: Data 
Curation, Project Administration, Writing – Review & Editing; Evans EE: Data Curation, Investigation, Project Administration, Writing – 
Review & Editing; Rajsasingham R: Writing – Review & Editing; Williams DA: Data Curation, Investigation, Project Administration, 
Writing – Review & Editing; Muzoora C: Investigation, Writing – Review & Editing; Creswell FV: Investigation, Writing – Review & Editing; 
Rhein J: Conceptualization, Investigation, Methodology, Writing – Review & Editing; Bond DJ: Writing – Original Draft Preparation, 
Writing – Review & Editing; Nakasujja N: Conceptualization, Methodology, Writing – Original Draft Preparation, Writing – Review & 
Editing; Meya DB: Conceptualization, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Writing – 
Review & Editing; Boulware DR: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, 
Resources, Software, Supervision, Writing – Review & Editing;
Competing interests: Dr. Boulware collaborates with multiple pharmaceutical companies making novel antifungal medicines for 
cryptococcal meningitis in public-private research partnerships, without any financial interests or payments from these companies. 
Gilead has provided grants and Ambisome antifungal medication to the Infectious Disease Institute in Uganda and Meningitis 
Foundation for cryptococcal meningitis-related research. However, no investigators have financial interests or have received funding 
from Gilead.
Grant information: This work was supported by the Wellcome Trust through a Clinical PhD Fellowship to FVC [210772] and through the 
Joint Global Health Trials scheme jointly funded by the UK Medical Research Council, UK Department for International Development and 
the Wellcome Trust [M007413/1]. This research was also supported by the National Institute of Neurologic Diseases and Stroke, the 
Fogarty International Center [R01NS086312, R25TW009345], the National Institute of Allergy and Infectious Diseases [T32AI055433], the 
National Institute of Mental Health [K23MH121220], and Grand Challenges Canada [S4-0296-01]. 
Copyright: © 2021 Lofgren SM et al. This is an open access article distributed under the terms of the Creative Commons Attribution 
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
How to cite this article: Lofgren SM, Velamakanni SS, Huppler Hullsiek K et al. The effect of sertraline on depression and 
associations with persistent depression in survivors of HIV-related cryptococcal meningitis [version 1; peer review: 1 approved 
with reservations] Wellcome Open Research 2021, 6:45 https://doi.org/10.12688/wellcomeopenres.16363.1
First published: 26 Feb 2021, 6:45 https://doi.org/10.12688/wellcomeopenres.16363.1 
respectively. At three months, sertraline-treated subjects had 
consistent risk for depression as placebo-treated subjects but were 
significantly less likely to have severe depression (CES>26) (OR 0.335; 
95%CI, 0.130-0.865). Of those with depression at one month, 
sertraline-treated subjects were less likely than placebo-treated 
subjects to be depressed at three months (p=0.05). Sertraline was the 
only factor we found significant in predicting persistent depression at 
three months among those who had depression at one month. 
Conclusions: Depression is highly prevalent in HIV-infected persons 
who have survived cryptococcal meningitis. We found that sertraline is 
associated with a modest reduction in depression in those with 
depression at baseline and a significant decrease in severe 
depression.
Keywords 
Depression, HIV, sertraline, Antidepressive Agents, Depressive 
Disorder, Treatment-Resistant, biomarkers
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Introduction
Chronic illnesses, particularly when advanced, are associ-
ated with deterioration in mental health1. More than 300 
million individuals suffer from major depressive disorder 
worldwide2. In persons living with HIV/AIDS, the prevalence 
of depression is up to three times more common than in the 
general population3,4, making depression one of the most com-
mon neuropsychiatric complications in these individuals5. The 
under-diagnosis of major depression in people with HIV6 undoubt-
edly contributes negatively to individuals’ overall well-being. 
People diagnosed with depression and HIV-infection often 
have poorer clinical and HIV outcomes than those diagnosed 
with HIV infection without depression7,8. Treatment for depres-
sion in people living with HIV/AIDS utilizes the same main-
stays for treatment of depression as in the general population: 
antidepressant medication and talk therapy9. However, there is 
surprisingly little data on the efficacy of depression therapies 
in individuals with HIV10–12.
Here we present data on the rates of depression in participants 
in a cryptococcal meningitis trial, the effects of sertraline on 
said depression, and risk factors for persistent depression in 
this cohort. This work is a secondary analysis of a randomized, 
double-blind, placebo-controlled clinical trial that investigated 
the utility of adjunctive sertraline as a putative antifungal medi-
cine among persons with AIDS and cryptococcal meningi-
tis, Adjunctive Sertraline for the Treatment of HIV-Associated 
Cryptococcal Meningitis (ASTRO-CM)13. The trial assessed 
depression via the Center for Epidemiologic Studies Depres-
sion Scale (CES-D) as a secondary endpoint. We sought to eval-
uate the effect of sertraline on the prevalence and severity of 
depression in cryptococcal meningitis survivors who had been 
in the randomized trial. We also assessed risk factors for and 
the prevalence of depression among pooled prospective cohorts 
from 2010–2017, including ASTRO-CM, among Ugandans 
surviving cryptococcal meningitis.
Methods
For this paper, we used data from the ASTRO-CM 
randomized trial13. In ASTRO-CM, we prospectively consented 
460 HIV-infected adults who tested positive for cerebrospinal 
fluid (CSF) cryptococcal antigen at Mulago National Referral 
Hospital in Kampala, Uganda from March 2015 to May 2017. 
All participants received intravenous amphotericin B deoxy-
cholate (0.7–1.0 mg/kg/day) with oral fluconazole 800mg/day. 
Participants were treated for meningitis as an inpatient for at least 
one week. They were randomized to receive either adjunctive 
sertraline or placebo; 229 participants started with 400mg/day 
of sertraline, while 231 received the placebo13. Dosing was 
for antifungal treatment and double the maximum dose for 
depression. Depression scores were evaluated at one and three 
months using the CES-D scale, a self-reported questionnaire 
comprised of 20 items representing overall mood and feelings. 
Given how ill participants are with cryptococcal meningitis, they 
were not screened for depression as an inpatient or otherwise 
prior to their one-month outpatient visit. We defined depression 
as a CES-D score of >15 on a 0 to 60-point total 
scale14,15. Mulago National Referral Hospital (MREC 429) and 
the University of Minnesota Institutional Review Boards 
(1304M31361) approved the protocol. Written informed consent 
was provided by all participants or their surrogates.
We compared subjects with depression (CES-D scores >15) 
to subjects without depression (CES-D score 0–15) on demo-
graphic factors, including gender and age, clinical charac-
teristics, such as viral load, fungal burden, antiretroviral 
medications, mental status based on Glasgow Coma Scale, and 
persistent depression. We compared continuous variables using 
Mann-Whitney U and categorical variables using Chi-square. 
We repeated the analysis in the sub-group of subjects with severe 
depression using the CES-D cutoff ≥2616. We further examined 
the effect of sertraline versus placebo within the ASTRO-CM 
randomized trial alone (n=460) regardless of depres-
sion status at one month. Finally, we evaluated the data as 
might be done in an antidepressant drug trial looking at 
those depressed at baseline (one month) and the change in 
CESD score, response rate, and remission rates.
We next looked at demographic associations with persist-
ent depression at three months. We first evaluated this in the 
ASTRO-CM randomized trial alone, followed by a sensitivity 
analysis for baseline associations of persistent depression. In this 
sensitivity analysis, we included two other cohorts of cryptococ-
cal meningitis survivors, which also evaluated participants for 
clinical depression. One of these cohorts included 172 subjects 
enrolled as a part of the ASTRO-CM pilot phase II trial. 
In this pilot study, participants received varying doses of sertra-
line (100 mg to 400 mg daily) for the first two weeks (n=172), 
followed by 200 mg sertraline daily until 3-months when it was 
subsequently tapered17. The second cohort, the Cryptococcal 
Optimal Antiretroviral therapy Timing (COAT) trial, enrolled 
177 subjects and assessed early versus deferred initiation of HIV 
therapy; participants did not receive sertraline in this cohort18. 
We calculated odds ratios to assess for risk of depression. 
Both the analysis and graphing were performed using Micro-
soft Excel version 16 (Redmond, WA) and IBM SPSS Statistics 
version 26 (Armonk, NY).
Results
We enrolled 460 persons with a first episode of cryptococcal 
meningitis into the ASTRO-CM sertraline randomized trial. As 
previously reported, the median age of the enrolled partici-
pants was 35 years13. The median CD4 count was 15 cells/mcL, 
and 41% of the enrolled subjects were women. Baseline char-
acteristics are shown in Table 119. There were no significant 
differences at baseline by randomized groups. Overall, 273 (59%) 
survived more than a month, and 234 (51%) survived through 
more than 3 months.
Differences between those screened and unscreened 
for depression
We selected those who survived to one month and compared 
those who were screened for depression and those not screened. 
Overall, 273 (59%) had survived >1 month and 234 (51%) 
survived through >3 months. Of subjects who survived to one 
month 174 (64%) had depression screening performed at one month 
and 169 (72%) at three months. 
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Those in ASTRO-CM not screened for depression at 
three months, but were still alive, had higher mortal-
ity (p<0.001), a higher CSF opening pressure >200 mmH
2
O 
(p=0.024), and had a higher depression score at one month 
(p=0.025) compared to those screened for depression at three 
months. These findings suggest that the reason for not screening 
for depression was related to illness.
Impact of sertraline on depression
We screened 174 participants for depression at one or three 
months using the CES-D scoring criteria. At one and three 
months, 62% (108/174) and 44% (74/169) of all subjects had 
depression. At three months, those receiving sertraline were 
non-significantly more likely to be depressed compared to those 
receiving placebo (37% vs. 64%, p=0.091).
We assessed subgroups of those who may have benefited 
from sertraline. Depression categories were subdivided into no 
depression (CES-D <16), moderate depression (CESD 16–25), 
and severe depression (CES-D ≥26). Those receiving sertraline 
were significantly less likely to have severe depression at three 
months versus moderate or no depression compared to those 
not on sertraline (p=0.030).
In Figure 1, a population pyramid is displayed comparing the 
CES-D score based on sertraline or placebo at one and three 
months. Sertraline had little effect on depression at one 
month, with no significant differences between groups. There 
was a similar percentage of people with depression 
receiving sertraline compared with placebo (62.2% vs. 
61.9%, p=0.966), and more with severe depression (38.1% vs. 
27.8% p=0.147). However, by three months, there were lower 
rates of depression in individuals receiving sertraline versus those 
receiving placebo (36.5% vs. 49.5%, p=0.091), though not sta-
tistically significant. At three months, significantly fewer partici-
pants receiving sertraline had severe depression when compared 
with those that received placebo (8.1% vs. 24.2%, p=0.006).
Outside a clinical trial using sertraline as an antifungal, a 
patient would typically only be prescribed an anti-depressant as 
an outpatient. Therefore, we examined those 135 who had 
depression (CES-D ≥16) at one-month post meningitis diagnosis, 
Table 1. Baseline characteristics in randomized Adjunctive Sertraline for the Treatment of 
HIV Associated Cryptococcal Meningitis (ASTRO-CM) Trial.
Placebo 
(N=231) Median (IQR) 
or N(%)
Sertraline 




   Age, years  35 (30-41)  35 (29-40)  0.234 
   Women  37.7%  97 (42.4%) 0.304 
   CD4 cell count, cells/mm3  13 (6-41)  17 (7-47) 0.362 
   Receiving ART  48.1%  48.9% 0.854 
Baseline CSF Analysis
   Opening pressure, mm H2O  270 (180-410)  248 (170-380) 0.172 
   Opening pressure >200 mm H2O  68.5%  60.7% 0.100 
   Cryptococcal culture, log10 CFU/mL 4.82 (3.63-5.55)  4.78 (3.56-5.62) 0.946 
   Sterile culture  6.6%  11.0% 0.098 
   CSF white-cell count >5 cells/mm3 66.2%  58.4% 0.088 
   CSF protein, mg/dL 42 (22-100)  47 (23-106) 0.576 




   Day 14 CSF opening pressure, 
mmH2O
200 (130-300) 200 (150-300) 0.539
*P-values from continuous variables calculated with Mann-Whitney U, p-values from categorical variables calculated 
with Pearson Chi-square (2-sided).
**2nd LP at day 2–5 and N=199.
IQR= Interquartile Range, ART= Antiretroviral Therapy, CSF= Cerebrospinal Fluid.
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Figure 1. Population Pyramid Comparing CES-D score by sertraline or placebo at one and three months.
which is the time of entering into outpatient HIV care. We 
also evaluated the baseline (one month) to endpoint (three 
month) change in CES-D score for sertraline versus placebo. 
We found that the median (IQR) change was 8 (-2.5–19.5) 
for sertraline versus 5 (-2–12), p=0.095. We also evaluated the 
response rate of 50% improvement in CES-D score from one 
to three months. We found that the response rate for sertraline 
was 50% compared to 33.8% for placebo (p=0.056). As stated 
above, the percentage of resolved depression was not statistically 
better for sertraline than placebo (p=0.091).
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Baseline factors associated with persistent depression 
at three months in ASTRO-CM sertraline randomized 
control trial
Factors associated with persistent depression at three months 
in the randomized ASTRO-CM sertraline trial were evaluated 
(Table 219). A higher percentage of women (44 (59.5%)) and 
those with Glasgow coma scale <15 (33 (44.6%)) trended towards 
being more likely to be depressed (CES-D >15). Depression at 
one month was not associated with depression at three months 
(65% vs. 55%, p=0.286).
Baseline factors associated with persistent depression 
at three months in combined cohorts
Factors associated with persistent depression at three months 
were examined from the combined cohorts of 883 participants 
(2010–2017) to determine if our findings were generalizable. 
In the combined cohorts, 66.3% and 38.5% of subjects had 
depression at one and three months, respectively. Those with 
depression at three months were less likely to be from Kampala 
(82.5% vs. 96.2% p<0.001) and were more likely to have a 
Glasgow Coma Score (GCS) <15 at entry (37.7% vs. 26.5%, 
Table 2. Factors associated with persistent depression at three Months in 











CES-D Score at three months 23 (18-30) 8 (4-11) ----
Demographics
       Age, years  34.5 (29.0-40.0) 35.0 (29.0-38.0) 0.313
       Women 40.5% 28.4% 0.098
Clinical characteristics
       Glasgow Coma Scale Score <15 44.6% 31.6% 0.083
       CD4 cell count, cells/mm3  16 (7-51) 19 (8-52) 0.996
       Receiving ART 40.5% 49.5% 0.247
Baseline CSF Analysis
       Opening pressure, mm H2O  265 (180-370) 260 (200-340) 0.919
       Opening pressure >200 mm H2O  64.5% 73.3% 0.254
       Cryptococcal culture, log10 CFU/mL 4.6 (3.4-5.3) 4.7 (3.4-5.3) 0.802
       Sterile CSF cryptococcal culture 6.8% 9.5% 0.542
       CSF white-cell count ≥5 cells/mm3 45.7% 44.2% 0.848
       CSF protein, mg/dL 50.0 (20-141.5) 49.5 (20.8-120.0) 0.638
Follow-up CSF Analysis
       Day 14 CSF Opening pressure >200 43.2% 51.9% 0.393
Depression at One Month
       CES-D Score  20 (14-28) 18 (11-27) 0.368
       % Depressed (CES-D >16) 64.5% 54.9% 0.286
*P-values from continuous variables calculated with Mann-Whitney U, p-values from categorical 
variables calculated with Pearson Chi-Square. 
CES-D= Center for epidemiologic studies depression scale, IQR= Interquartile Range, ART= Antiretroviral 
Therapy, CSF= Cerebrospinal Fluid
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p= 0.043). Sertraline was not associated with a difference in 
depression (41.2% vs. 48.4%, p=0.231) in the combined 
cohorts.
Discussion
This analysis of participants with cryptococcal meningitis 
reveals that sertraline given regardless of depression status in 
the ASTRO-CM sertraline randomized trial did not significantly 
reduce depression. The change in CESD, response rate, and 
remission rate were not significantly better in sertraline com-
pared to placebo among all comers. Sertraline did significantly 
lower the prevalence of severe depression in those recovering 
from cryptococcal meningitis for all-comers. Further, sertraline 
was associated with significantly less depression at three 
months in those with depression at one month.
The percentage of participants with depressive symptoms at one 
month was 67% in ASTRO-CM, which likely represents major 
depression, as well as acute adjustment disorder, pain, severe 
illness, and appropriate anxiety. At three months, the percentage 
of participants with depressive symptoms was 44% in 
ASTRO-CM. While this still is affected by pain, illness, 
and other factors, it is likely a better measure of depres-
sion symptoms than other causes. For this reason, we based 
our depression outcomes on three and not one-month outcomes.
The participants in this study had multiple reasons to have 
depressive symptoms at one and three months. As the subjects 
had just survived a critical illness, they were still quite ill with 
advanced HIV, and many had yet to start or re-start HIV medi-
cation. Most participants had not worked for weeks to months, 
and many had just disclosed their HIV status to their loved ones 
for the first time. In the open wards of the hospital, the indi-
viduals in the study knew other participants who had died and 
understood better than most, the mortality associated with cryp-
tococcal meningitis. Anecdotally, our staff found that counseling 
and social support helped participants considerably.
In the combined cohorts, individuals who were from areas 
outside of Kampala, as well as those who had a GCS<15, were 
found to have higher rates of depression. This association with 
location could be due to limited financial resources and the 
inability to access necessary healthcare in outlying areas. Those 
with GCS <15 were sicker, which may be associated with 
more symptoms such as headaches and needing more frequent 
lumbar punctures. However, there was no variation in the fungal 
burden between the groups.
Participants who had their CES-D measured in this study 
were well enough to attend outpatient clinic and answer 
survey questions. Not only did these participants have 
lower fungal burdens, but they were also less likely to have 
altered mental status and had decreased mortality rates. This 
selection bias of mortality for those screened for depres-
sion is a limitation of this study, but one true of all studies with 
critically ill individuals.
Only a few preexisting studies have previously evaluated depres-
sion and cryptococcal meningitis. We found one case report 
of an HIV-positive individual with depression associated with 
cryptococcal meningitis20, a case series of HIV-negative individu-
als with cryptococcal meningitis21, and two case reports where 
HIV-statuses were not revealed22,23. We believe this is the first 
large study of depression following cryptococcal meningitis 
diagnosis, and the first randomized, controlled trial of a selective 
sertraline reuptake inhibitor (SSRI) in those with cryptococcal 
meningitis.
There is surprisingly little data about the use of antidepres-
sants in Africans living with HIV. In South Africa, Hoare et al. 
conducted a randomized controlled trial of escitalopram in 
those with HIV-associated depression24. The results of this study 
were null; however, they only used a starting dose of escitalo-
pram and did not increase the dose or change SSRIs. A recent 
Cochrane review found some data demonstrating that SSRIs 
were effective in people with HIV, but none of these stud-
ies took place in Africa, and the data were inadequate10. Further 
work is therefore desperately needed given the large numbers of 
Africans living with HIV and the high prevalence of depression 
in this population25–28.
Limitations
In this study, the participants evaluated were seriously ill with 
cryptococcal meningitis and AIDS. They were given high dose 
sertraline at enrollment but had depression only measured at 
one and three months, and one month was taken as the base-
line measurement. Many individuals died in the first two weeks. 
Thus, those individuals were not included in one or three-month 
measurements. CES-D was not measured at baseline, given 
the prevalence of decreased GCS <15 or more subtle signs of 
altered mental status, as well as overall poor health such as 
headache, nausea, and vomiting. This study may not have 
generalizability to those without meningitis; however, this is 
one of the first placebo-controlled randomized control trial of 
SSRIs in Africans with HIV.
Conclusion
Depression has a high prevalence in survivors of cryptococ-
cal meningitis. We found that sertraline was non-significantly 
associated with reduced depression in those with depression at 
baseline and significantly associated with severe depression in 
all-comers. Larger randomized, controlled trials are needed 
examining depression in those with the general HIV population.
Data availability
Underlying data
DRYAD: The effect of sertraline on depression and associa-
tions with persistent depression in survivors of HIV-related 
cryptococcal meningitis. https://doi.org/10.5061/dryad.n5tb2rbtr19
This project contains the following underlying data:
-    Combined_CM_Depression_Database.xlsx (CM patient 
depression data)
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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Abstract 
“Depression is a risk factor for worse outcomes in persons living with HIV/AIDS…” - What type of 
outcomes? 




This study is not about people with chronic illness. It is a specific population. Please rewrite the 
introduction to focus on the population addressed by this study. 
 
Results 
“The median CD4 count was 15 cells/mcL” - Please use standard units: mm3, as used in table 1. 
 
Discussion 
Please compare the dosing of Sertraline in this study with usual dosing/frequency as an 
antidepressant. Also, what is known about time to effectiveness. Given that it generally takes 4-6 
weeks to work, how would this be anticipated to affect the outcomes of this trial? 
 
There is a section in the discussion summarizing data on use of data use of antidepressants in 
Africans living with HIV. Please expand to summarize what is known about use of antidepressants 
in people living with HIV in general. Given what is known, is sertraline a rational choice? Also, 
please summarize other evidence-based interventions for treating depression among people 




Page 9 of 10
Wellcome Open Research 2021, 6:45 Last updated: 19 APR 2021
1. Nakimuli-Mpungu E, Musisi S, Wamala K, Okello J, et al.: Effectiveness and cost-effectiveness of 
group support psychotherapy delivered by trained lay health workers for depression treatment 
among people with HIV in Uganda: a cluster-randomised trial.Lancet Glob Health. 8 (3): e387-e398 
PubMed Abstract | Publisher Full Text  
 
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: HIV epidemiology
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
 
Page 10 of 10
Wellcome Open Research 2021, 6:45 Last updated: 19 APR 2021
